[
  {
    "project_id": "PROJ_2023_001",
    "title": "Anti-TNF Nanobody Optimization for Adalimumab Biosimilar",
    "target": "TNF-Î± binding",
    "objective": "Improve binding affinity and reduce immunogenicity",
    "timeline_weeks": 10,
    "cycles_completed": 4,
    "final_kd_nm": 0.3,
    "success_factors": [
      "CDR3 loop engineering was most effective",
      "Expected Improvement acquisition function optimal for initial cycles",
      "Framework mutations improved stability without affecting binding"
    ],
    "methodology": {
      "acquisition_strategy": "EI for exploration, UCB for exploitation",
      "variants_per_cycle": 8,
      "convergence_criteria": "KD < 0.5 nM or model uncertainty < 0.1"
    }
  },
  {
    "project_id": "PROJ_2023_015", 
    "title": "vWF A1 Domain Nanobody Development",
    "target": "von Willebrand Factor A1 domain",
    "objective": "Develop high-affinity nanobody for thrombotic disorders",
    "timeline_weeks": 8,
    "cycles_completed": 3,
    "final_kd_nm": 0.8,
    "success_factors": [
      "Targeted CDR1 and CDR3 mutations most effective",
      "SPR assays with HBS-EP+ buffer provided consistent results",
      "Expression yield monitoring prevented stability issues"
    ],
    "methodology": {
      "acquisition_strategy": "Balanced EI/UCB approach",
      "variants_per_cycle": 6,
      "convergence_criteria": "Target KD achieved or 3 consecutive cycles without improvement"
    }
  },
  {
    "project_id": "PROJ_2022_087",
    "title": "Caplacizumab Affinity Enhancement Project", 
    "target": "vWF A1 domain binding optimization",
    "objective": "Enhance Caplacizumab binding affinity for improved efficacy",
    "timeline_weeks": 12,
    "cycles_completed": 5,
    "final_kd_nm": 0.4,
    "success_factors": [
      "Multi-point mutations in CDR3 achieved breakthrough",
      "Active learning reduced experimental burden by 40%",
      "Gaussian Process model accuracy improved with each cycle"
    ],
    "methodology": {
      "acquisition_strategy": "Adaptive EI with increasing exploitation",
      "variants_per_cycle": 10,
      "convergence_criteria": "KD < 0.5 nM and model confidence > 0.9"
    }
  }
]